Ποια είναι η τιμή για Oragenics, Inc. (OGEN)

Η τιμή για Oragenics, Inc. (OGEN) είναι $0.5301

Ποια είναι η κεφαλαιοποίηση αγοράς για Oragenics, Inc. (OGEN)

Η κεφαλαιοποίηση αγοράς για Oragenics, Inc. (OGEN) είναι $2.39M

Oragenics, Inc. (OGEN) Τιμή και Κεφαλαιοποίηση Αγοράς

Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.

Η τιμή για OGEN	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$1,208,270 $2.39M	NVDA	$5.452T	+227,932,432.63%
$995,101 $2.39M	AAPL	$4.490T	+187,719,360.33%
$922,494 $2.39M	GOOG	$4.162T	+174,022,458.87%
$814,770 $2.39M	MSFT	$3.676T	+153,700,995.48%
$627,873 $2.39M	AMZN	$2.833T	+118,444,185.94%

Η τιμή για OGEN

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$1,208,270 $2.39M